Fluorouracil, Cisplatin, Leucovorin Calcium, and Cetuximab in Treating Patients With Adenocarcinoma of the Stomach or Gastroesophageal Junction

OBJECTIVES:

Primary

• To evaluate the objective response rate according to RECIST V1.1 criteria in patients with adenocarcinoma of the stomach or gastroesophageal junction treated with neoadjuvant chemotherapy comprising fluorouracil, cisplatin, leucovorin calcium, and cetuximab followed by surgery and adjuvant chemotherapy.
• To determine the non-toxicity rate in these patients.

Secondary

• To determine the rate of macroscopically and microscopically complete surgical resection (R0).
• To determine the overall tolerance in patients treated with this regimen.
• To determine post-operative mortality and morbidity in these patients.
• To determine the rate of recurrence at 1 and 2 years in these patients.
• To determine recurrence-free survival at 3 years in these patients.
• To determine disease-free survival at 3 years in these patients.
• To determine overall survival at 3 years in these patients.
• To determine quality of life using EORTC QLC-C30 and STO-22 questionnaires.
• To determine the correlation between the response rate and the degree of skin toxicity.

OUTLINE: This is a multicenter study.

• Neoadjuvant therapy and surgery: Patients receive leucovorin calcium IV over 2 hours, cisplatin IV, fluorouracil IV continuously over 46 hours, and cetuximab IV over 1-2 hours on day 1. Treatment repeats every 2 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. Within 3-4 weeks after completing neoadjuvant chemotherapy, patients undergo surgery.
• Adjuvant therapy: Within 4-8 weeks after completing neoadjuvant chemotherapy, patients receive leucovorin calcium, cisplatin, fluorouracil, and cetuximab as in neoadjuvant therapy. Treatment repeats every 2 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.

Patients complete quality-of-life questionnaires (QLC-C30 and STO-22) periodically. Blood and tissue samples are collected periodically for correlative and translational studies.

After completing study therapy, patients are followed up every 4 months for 2 years and then every 6 months for 1 year.

DISEASE CHARACTERISTICS:

• Histologically confirmed adenocarcinoma of the stomach or gastroesophageal junction

• Stage IB, II, or III disease according to TNM classification OR type I, II, or III disease according to Siewert classification

• TNM: T1N1-3, T2N0-3, T3N0-3, or T4N0-3 (no T1N0 or M1)
• Disease considered operable with curative intent
• No gastric scirrhous carcinoma (linitis plastica)

• Forms with independent cells are not considered linitis
• Measurable disease according to RECIST V1.1
• No planned esophagectomy without thoracotomy in patients with adenocarcinoma of the gastroesophageal junction type I

PATIENT CHARACTERISTICS:

• WHO performance status 0-2
• Polynuclear neutrophil count ≥ 1,500/mm³
• Platelet count ≥ 100,000/mm³
• Creatinine clearance > 50 mL/min
• Bilirubin < 1.5 times normal
• Serum albumin > 30 g/L
• Prothrombin time ≥ 80%
• FEV1 > 1 L in case of thoracotomy
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• No known cirrhosis
• No other progressive condition that has not been stabilized including the following:

• Hepatic failure
• Renal failure
• Respiratory failure
• NYHA class III-IV congestive heart failure
• Unstable angina
• Myocardial infarction in the past 6 months
• Significant arrhythmias in the past 12 months
• No recent weight loss exceeding 15%
• No interstitial pneumonia
• No other malignant tumor within the past 5 years except for basal cell skin carcinoma or cancer in situ of the cervix
• No psychological, familial, or geographical reasons that will preclude the patient being monitored regularly
• No persons deprived of liberty or under guardianship (Disability Act)

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics
• No prior chemotherapy or radiotherapy for gastric cancer
• No other concurrent anticancer treatment, immunotherapy, or hormone therapy
• No prior abdominal or thoracic radiotherapy